Cite
Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study.
MLA
Hansen, Martin Lundsgaard, et al. “Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study.” PLoS ONE, vol. 9, no. 5, May 2014, pp. 1–10. EBSCOhost, https://doi.org/10.1371/journal.pone.0097605.
APA
Hansen, M. L., Fallentin, E., Lauridsen, C., Law, I., Federspiel, B., Bæksgaard, L., Svendsen, L. B., & Nielsen, M. B. (2014). Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. PLoS ONE, 9(5), 1–10. https://doi.org/10.1371/journal.pone.0097605
Chicago
Hansen, Martin Lundsgaard, Eva Fallentin, Carsten Lauridsen, Ian Law, Birgitte Federspiel, Lene Bæksgaard, Lars Bo Svendsen, and Michael Bachmann Nielsen. 2014. “Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study.” PLoS ONE 9 (5): 1–10. doi:10.1371/journal.pone.0097605.